October 5, 2022: “The updated warning gives parents clear advice on how to avoid the possible hazards of using bouncer seats. In addition, making the safety standard mandatory will help ensure widespread compliance by manufacturers.”
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
National Center For Health Research Comments on Consumer Product Safety Standards for Frame Child Carriers
September 29, 2022 We are writing to express our strong support for the Consumer Product Safety Commission (CPSC) plan to adopt a mandatory standard for frame child carriers to improve safety by including more stringent requirements and test conditions. The National Center for Health Research (NCHR) is a nonprofit think tank that conducts, analyzes, and […]
Read More »Testimony of Diana Zuckerman at the Meeting of EPA’s National Environmental Justice Advisory Council on September 28, 2022
September 28, 2022: I want to comment very briefly on the PFAS recommendations, since that’s an issue we’ve worked on for years. Let me add that we are very concerned about all endocrine disrupting chemicals not just PFAS.
Read More »Testimony of Dr. Diana Zuckerman About PEPAXTO FDA Advisory Committee Meeting on September 22, 2022
We testified before the FDA Advisory Committee that Pepaxto should no longer be approved for multiple myeloma because new research shows that patients taking it died 5 months sooner than patients taking a different treatment.
Read More »NCHR Letter to Sen. Smith in Support of Women’s Health Legislation
September 22, 2022: Two bills led by Sen. Smith take critical steps to help protect access to safe and effective reproductive health care products. We at NCHR are appreciative of her work to act in the face of the many challenges presented following the Dobbs decision.
Read More »